IPSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Century Therapeutics Inc (IPSC) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators show an overbought condition, and the stock has a high probability of short-term declines. Additionally, the financial performance is weak, with no revenue and negative net income, despite slight improvements in EPS and net income YoY. While analysts have a positive long-term view, the lack of recent news, no significant insider or congress trading, and hedge funds selling heavily suggest caution. The options data also indicates low put-call ratios, which may reflect limited interest or activity. For a long-term investor, it would be better to wait for clearer signs of growth or stability.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 83.576, signaling an overbought condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near resistance levels (R1: 2.546), and a pullback is likely.
Analysts initiated coverage with a Buy rating, citing promising preclinical data for CNTY-813 and long-term shareholder value potential.
Hedge funds are selling heavily, with a 179.43% increase in selling activity last quarter. Financial performance is weak, with no revenue and negative net income. The stock has a high probability of short-term declines based on candlestick pattern analysis.
In Q3 2025, revenue dropped to $0 (-100% YoY). Net income improved slightly to -$34.42M (+10.24% YoY), and EPS increased to -0.4 (+8.11% YoY). Gross margin remains at 100%. Overall, financials are weak with no revenue generation.
TD Cowen initiated coverage with a Buy rating, citing promising preclinical data for CNTY-813 and potential long-term value as the pipeline advances.
